Calcium pyrophosphate deposition disease: current state of the problem

Kovalenko V.M.¹, Dubkova A.G. ², Krylova A.S.², Giresh I.I.¹, Silantieva T.S.²

• ¹SU «National Scientific Center «Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M. D. Strazhesk of the National Academy of Sciences of Ukraine»
• ²Shupyk National Healthcare University of Ukraine, Kyiv

Summary. Objectives. Calcium pyrophosphate deposition disease is a common cause of acute and chronic arthritis caused by the deposition of calcium pyrophosphate crystals in the joints and soft tissues, leading to joint inflammation and damage. It has a wide spectrum of clinical manifestations and often present challenges to diagnosis and management as it commonly affects elderly patients with comorbidities. Aim. The aim of this article was to review the literature and highlight current aspects of treatment and monitoring of calcium pyrophosphate deposition disease. Methods. The scientific search in printed and electronic editions, scientific search databases Medline and PubMed using methods of analysis, comparison and generalization of information data is carried out. Relevant articles on the monitoring and treatment of calcium pyrophosphate deposition disease have been identified and reviewed. Results. The article presents new classification criteria for calcium pyrophosphate dihydrate crystal deposition disease, published in 2023. The authors of the review studied the current recommendations of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) foe diagnosis and treatment. The article discusses the issue of therapy of calcium dihydrate pyrophosphate crystal deposition disease. New data on the appointment of biological therapy and new directions of treatment were analyzed. Conclusions. The disease of calcium pyrophosphate deposition disease is an urgent problem of modern rheumatology, which still has many questions and directions that require further research. Current therapy for CPPD arthritis lacks robust evidence, but the new 2023 classification criteria for CPPD will facilitate more clinical research on this common crystal arthropathy, with well-defined patient cohorts which will facilitate the production of high-quality evidence to guide the management of this condition in the future.